ΔPSap4#5 surface-functionalized abiraterone-loaded nanoparticle successfully inhibits carcinogen-induced prostate cancer in mice: a mechanistic investigation
Abstract Prostate cancer (PCa) is one of the fatal illnesses among males globally. PCa-treatment does not include radiotherapy. Chemotherapy eventually causes drug resistance, disease recurrence, metastatic advancement, multi-organ failure, and death. Preclinical data on PCa-induced by carcinogens a...
Main Authors: | Ashique Al Hoque, Debasmita Dutta, Brahamacharry Paul, Leena Kumari, Iman Ehsan, Moumita Dhara, Biswajit Mukherjee, Mohiuddin Quadir, Benny Abraham Kaipparettu, Soumik Laha, Shantanu Ganguly |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-09-01
|
Series: | Cancer Nanotechnology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12645-023-00223-5 |
Similar Items
-
Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Pedro Cardoso, et al.
Published: (2020-05-01) -
Abiraterone Acetate Withdrawal Syndrome: Does It Exist
by: Hélène Gauthier, et al.
Published: (2012-07-01) -
Prescription pattern of abiraterone in Brazil - a survey of medical oncologists
by: João Pedro Homse-Netto, et al.
Published: (2023-08-01) -
A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer
by: Masaru Tani, et al.
Published: (2023-09-01) -
Synthesis and Preclinical Evaluation of Small-Molecule Prostate-Specific Membrane Antigen-Targeted Abiraterone Conjugate
by: Aleksei E. Machulkin, et al.
Published: (2022-12-01)